Introduction
Prostate cancer is one of the most common cancers in men worldwide (1) . Radical prostatectomy can cure appropriately selected patients with localized disease, as can radiation therapy. Imaging for staging at the time of diagnosis varies slightly depending on the patient's overall risk of extraprostatic disease, but patients classified as intermediate risk or higher will undergo skeletal scintigraphy and either an abdominopelvic CT or pelvic MRI for comprehensive staging per the National Comprehensive Center Network (NCCN) clinical practice guidelines (2) . Locally advanced prostate cancer is defined by the NCCN as T3b-T4 tumors, tumors with primary Gleason pattern of 5, or tumors with greater than four cores of Gleason grade group 4 or 5 (2) . Patients are deemed metastatic at initial staging if any distant or nodal metastasis is detected on conventional anatomic imaging (2) .
Following definitive treatment, patients will undergo serial serum PSA sampling to evaluate for response to treatment and to detect recurrence. Approximately 20-40% of patients undergoing radical prostatectomy and 30-50% of patients undergoing radiation therapy will experience biochemical recurrence within 10 years (3) (4) (5) . The American Urological Association defines biochemical recurrence in patients who have undergone prostatectomy as an initial PSA value of at least 0.2 ng/mL followed by a subsequent confirmatory PSA value of 0.2 ng/mL or more (6) . In patients who have undergone definitive primary radiation therapy, biochemical recurrence is defined as a rise of 2 ng/mL or more above the nadir PSA level (7) . Common locations of local recurrence are within the prostate gland, prostatectomy surgical bed, regional nodal metastases, and osseous metastases. Computed tomography (CT) and magnetic resonance imaging (MRI) are non-invasive modalities that have been utilized for
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Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer detection of metastatic nodal disease, largely relying on morphologic characteristics such as size and shape. A metaanalysis found a pooled sensitivity of 42% and specificity of 82% for CT imaging and similar 39% sensitivity and 82% specificity for detection of metastatic lymph nodes (8) . Metastatic nodal disease is determined largely by size when using CT and MR, with a threshold of 1.0 cm in short axis of oval nodes and 0.8 cm for round nodes used as indicators of likelihood of metastatic disease (9) . However, more than half of lymph nodes involved with metastatic prostate cancer may be less than 1 cm (10) . Furthermore, non-metastatic nodes may be enlarged due to reactive hyperplasia, leading to false positives. Imaging remains a crucial aspect of evaluation of the patient with biochemical recurrence, as a recurrence in the prostate bed or pelvic lymph nodes may be treated with surgery or salvage radiotherapy, while a more distant pattern of metastasis may require systemic treatment with either androgen deprivation therapy or chemotherapy (2) . However, anatomic imaging with CT and MRI alone has limited sensitivity for detection of nodal metastases from prostate cancer.
Positron emission tomography (PET) is an imaging technique that utilizes radiolabeled drugs to image molecular targets, metabolic pathways, and functional processes in cancer. A number of PET tracers have been developed that can increase the accuracy of prostate cancer detection compared to morphological imaging alone, particularly in the setting of biochemical recurrence. Significant research is currently being conducted to develop effective PET tracers that can be used for both initial staging and localization of biochemical recurrence in patients with prostate cancer. Additionally, several of the tracers that will be discussed including PSMA ligands are being evaluated not only for their diagnostic capabilities, but also for molecularly targeted radionuclide therapy. These agents are often called theranostics, and in this scenario imaging is used to select appropriate patients for therapy by non-invasively confirming the presence of the target prior to treatment. For example, the same agent can be labeled with a positron-emitting radionuclide such as gallium-68 for PET or with a therapeutic radionuclide such as lutetium-177 for treatment. In this article we will discuss and compare the PET tracers available for detection of prostate cancer in patients with biochemical recurrence.
Methods
A search was conducted through PubMed to assess the existing literature regarding the use of PET imaging in the setting of biochemically recurrent prostate cancer. Terms searched included "prostate cancer", "PET prostate cancer", and "PET biochemical recurrence". These searches were conducted on 12/4/2017. Articles were reviewed and included in the paper if they were scientific articles regarding PET imaging of biochemically recurrent prostate cancer, provided needed statistics on prostate cancer recurrence rates and/or mortality, or provided a useful summary or meta-analysis of the prostate cancer PET literature. Articles were excluded if they did not discuss PET imaging of biochemically recurrent prostate cancer or focused on non-PET imaging modalities of prostate cancer.
Basics of prostate cancer PET imaging and available tracers
PET is currently performed in combination with CT or MR for attenuation correction and anatomic localization of PET findings. The vast majority of clinical PET scanners currently are PET/CT systems, although PET/ MRI is in clinical use with an increasing installation base. In PET imaging for prostate cancer, a positron-emitting radiopharmaceutical is administered intravenously, and images are acquired through the detection of coincident gamma rays of 511 keV that result from the annihilation of a positron with an electron in a tissue (11) . PET images can provide quantitative localization of radioactivity throughout the body at a single or multiple time points after tracer injection.
The timing of imaging acquisition after PET tracer administration varies depending on the pharmacokinetics of the tracer. In some cases, image acquisition within 5 minutes after PET tracer administration is desirable to minimize the concentration of radioactivity in the urinary bladder and ureters. PET provides higher spatial and temporal resolution than conventional single photon computed tomography (SPECT). However, one of the limitations of PET is resolution, with decreased sensitivity of the detection and characterization of PET tracer uptake in lesions less than 8 mm. Additionally, PET tracers are expensive compared to CT and MRI contrast agents, and reimbursement for PET studies can be challenging even when the PET tracers are approved by the Food and Drug Administration (FDA).
A wide range of radionuclides have been used to label PET tracers for prostate cancer imaging. The radionuclides that have been used most commonly for PET tracers targeting prostate cancer are carbon-11, fluorine-18, and gallium-68, which vary in terms of their physical halflife and their chemical properties ( Table 1) . Fluorine-18 is widely available, and its 110 min half-life is sufficient for production in large quantities and distribution to other sites that do not have onsite production capabilities. Carbon-11 is readily produced on medical cyclotrons, but its 20 min half-life markedly limits distribution to other sites and requires significant coordination between the production and imaging team to obtain multiple patients dosages from a single carbon-11 production. Gallium-68 has a 68 min half-life and is typically produced using germanium-68 generator systems which facilitates on-site and on-demand production of 68 Ga-labeled tracers. There are efforts to develop cyclotron-based production methods for gallium-68, but this technology is not currently widely available.
In general, PET tracers used for evaluation of biochemical recurrence all demonstrate increasing rates of positivity as the serum PSA levels rise (12) (13) (14) (15) (16) GRPR, gastrin-releasing peptide receptor. PET/CT, including cost, availability of PET/CT scanners, and lack of soft tissue evaluation which can be performed with other PET tracers.
Choline is a substrate for the synthesis of phosphatidylcholine, which is the major phospholipid in the cell membrane (29) . Choline is incorporated into tumor cells after transport into prostate cancer cells and phosphorylation by choline kinase, which is upregulated in prostate cancer (30) . (2) .
Acetate is a naturally occurring substance that can enter the fatty acid metabolic pathway, which is overexpressed in prostate cancer cells (52) (Figure 5 ). Currently, [
11 C]acetate-PET/CT is used at fewer sites than choline radiotracers (53) . choline-PET/CT with additional studies demonstrating similar results between the two radiotracers (55, 56) . A similar limitation between the two radiotracers is that the sensitivity for detection of disease is correlated with PSA levels, with decreased performance for PSA levels of <2 ng/mL (53, 57, 58) .
Prostate specific membrane antigen (PSMA) ligands
PSMA is a transmembrane protein expressed by the prostate and overexpressed in prostate cancer (59) (Figure 6 ). PSMA has long been a target for imaging patients with metastatic prostate cancer and was originally the target of [ Galgano et al. PET imaging in biochemically recurrent prostate cancer significantly limited due to the targeting of the intracellular portion of the PSMA protein which permitted radiotracer binding only in the setting of cellular apoptosis or necrosis (36, (59) (60) (61) (62) (67) . Among the lesions that underwent surgical intervention or biopsy, 30 false-negative results were observed in a total of 4 patients with the rest of the lesion (n=416) classified as either true-positive or true-negative (67) . Of note, this study also demonstrated a 50% detection rate in patients with serum PSA of less than 0.5 ng/mL, a significant improvement compared to the existing literature for choline and acetate and a finding that has been replicated in additional studies (67, 68) . A recent meta-analysis was performed by Perera et al., in which 16 articles including 1,309 patients were evaluated (69) . When evaluating on a per-patient basis, the summary sensitivity and specificity were identical at 86% (69) . When analyzed on a per-lesion basis, summary sensitivity was 80% and specificity was 97% (69 fluorine, which has potential to significantly reduce the cost and increase the availability of PSMA ligand through batch production and remote distribution (70 RM2-PET/CT was helpful in localizing the recurrence in a majority of the cases (77) . An additional study examining the use of a 68 Ga-labeled bombesin analog for PET/CT in patients with both initial diagnosis of prostate cancer and biochemical recurrence demonstrated a sensitivity of 88%, specificity of 81%, and accuracy of 83% for primary prostate cancer and 70% sensitivity for detection of metastatic lymph nodes (78) . The same bombesin analog also correctly identified two of three cases of local recurrence both in the prostatectomy surgical bed and regional lymph nodes when compared to [ 11 C]acetate-PET/ CT (78) . Similar to PSMA ligands, bombesin agents are being examined for their potential theranostic capabilities in delivering targeted radiation via alpha-emitters or betaemitters (79) .
Therapies targeting androgen receptor signalling are a cornerstone of the treatment algorithm of prostate carcinoma, both for treatment-naïve patients and patients diagnosed with biochemical recurrence. Although not currently utilized in the clinical setting, PET imaging targeting the androgen receptor would therefore make sense in the setting of prostate cancer. The majority of preclinical and initial in-human work for PET imaging of androgen receptors has been with 16β- [ 18 F]DFHT (Figure 8 ).
An initial study examining the (83, 84) . As PET/MRI scanners become increasingly common, further research is needed to demonstrate the added value of PET/MRI both in the pretreatment and posttreatment settings.
Conclusions
Molecular imaging of prostate cancer continues to evolve as new radiotracers are studied and put into clinical practice. The use of both PET/CT and PET/MRI are an important diagnostic consideration for patients with biochemically recurrent prostate cancer, particularly if locoregional therapy is being considered. As newer PET radiotracers become approved, it will be important for larger prospective head-to-head studies to be performed if an optimal molecular imaging algorithm is to be developed. At this point in time, it appears that both [ 18 F]fluciclovine and PSMA tracers are superior to the older PET tracers, but little existing data exists directly comparing the two. Given the existing research in theranostics with both PSMA and GRPR tracers, these imaging agents may be the optimal agent if consideration is being given to targeted molecular therapy with alpha-emitters or beta-emitters.
